You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

CLINICAL TRIALS PROFILE FOR ONGLYZA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Onglyza

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00575588 ↗	52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period	Completed	Bristol-Myers Squibb	Phase 3	2007-12-01	Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin.
NCT00575588 ↗	52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period	Completed	AstraZeneca	Phase 3	2007-12-01	Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin.
NCT00614939 ↗	Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment	Completed	Bristol-Myers Squibb	Phase 3	2008-01-01	Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.
NCT00614939 ↗	Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment	Completed	AstraZeneca	Phase 3	2008-01-01	Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.
NCT00661362 ↗	Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes	Completed	Bristol-Myers Squibb	Phase 3	2008-06-01	Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Onglyza

Condition Name

Chart
Table

Condition Name for Onglyza
Intervention	Trials
Type 2 Diabetes	21
Type 2 Diabetes Mellitus	18
Diabetes Mellitus, Type 2	7
Diabetes Mellitus	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Onglyza
Intervention	Trials
Diabetes Mellitus, Type 2	51
Diabetes Mellitus	48
Glucose Intolerance	5
Prediabetic State	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Onglyza

Trials by Country

Map
Table

Trials by Country for Onglyza
Location	Trials
United States	211
China	58
United Kingdom	31
Canada	29
India	28
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Onglyza
Location	Trials
Texas	18
California	12
Florida	10
Ohio	10
Virginia	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Onglyza

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Onglyza
Clinical Trial Phase	Trials
Phase 4	25
Phase 3	20
Phase 2/Phase 3	1
[disabled in preview]	15
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Onglyza
Clinical Trial Phase	Trials
Completed	49
Unknown status	11
Recruiting	5
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Onglyza

Sponsor Name

Chart
Table

Sponsor Name for Onglyza
Sponsor	Trials
AstraZeneca	40
Bristol-Myers Squibb	14
The University of Texas Health Science Center at San Antonio	2
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Onglyza
Sponsor	Trials
Industry	55
Other	46
NIH	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.